Auszug
Unter Supportivtherapie versteht man unterstützende Maßnahmen, die Sicherheit und Verträglichkeit zytostatischer Chemotherapien oder anderer medikamentöser Maßnahmen, operativer Eingriffe oder einer Radiotherapie zur Behandlung der malignen Grunderkrankung optimieren. Im weiteren Sinn werden darunter teilweise auch flankierende lokale oder begleitende medikamentöse Behandlungen subsumiert, die Einzelsymptome oder den Gesamtverlauf der Grunderkrankung beeinflussen (z.B. Pleurodese bei malignem Erguss oder Analgesie bei Tumorschmerz).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301–1307
Bois A du, Lück HJ, Meier W et al. A randomized cinical trial of Cisplatin/Paditaxel versus Carboplatin/Paditaxel as first-line treatment in ovarian cancer. J Natl Cancer Inst 2003; 95: 1320–1330
Bruera E, Driver L, Barnes EA et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003; 21: 4439–4443
Dizon DS, Sabbatini PJ, Aghajanian C et al. Analysis of patients with epithelial ovarian cancer of fallopian tube carcinoma retreated with cisplatin after the development of carboplatin allergy. Gynecol Oncol 2002; 84: 378–382
Gomez R, Harter P, Traut A et al: Managements der Carboplatinallergie mit Skintest und Desensitivierung. Geburtsh Frauenheilk 2006; 67: 126 (# PO-O 03.07)
Hesketh PJ. Defining the emetogenicity of cancer chemotherapeutic regimens: relevance to clinical practice. The Oncologist 1999; 4: 191–196
Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997, 15: 103–109
Hilpert F, Stähle A, Tomé O et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy — a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005; 13: 797–805
Hughes WT, Armstrong D, Bodey GP et al. ISDA-Guidelines: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751
Kandel MJ, Löhr A, Harter P et al. Cisplatinum re-challenge in relapsed ovarian cancer patients with platinum re-induction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15: 780–784
Klastersky J, Paesmans M, Rubenstein EB et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038–3051
Link H, Böhme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG — German Cancer Society). Ann Hematol 2003; 82 (Suppl 2): S105–S117
Markman M. Gynecol Oncol 2002; 84: 353 (letter to the editor)
Perugia International Cancer Conference VII MASCC consensus on antiemetic therapy 29–31.03.2004. Verfügbar unter http://www. mascc.org/files/MASCC_guide-slides060804-1st_ed.pps
Rapoport BL, Uys A, Anderson R. Febrile neutropenia: prospective study to validate the MASCC (Multinational Association for Supportive Care in Cancer) risk index score. Proc Am Soc Clin Oncol 2003; Abstr. 2960
Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 21: 4083–4107
Robinson JB, Singh D, Bodurka-Bevers DC et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecological malignancies. Gynecol Oncol 2001; 82: 550–558
Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100: 2026–2046
Schuchter LM, Hensley ML, Meropol NJ et al. 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 21: 2895–2903
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Harter, P., Löhr, A. (2009). Supportivtherapie — Therapiebegleitung. In: Management des Ovarialkarzinoms. Onkologie aktuell. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68857-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-540-68857-0_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-41987-7
Online ISBN: 978-3-540-68857-0
eBook Packages: Medicine (German Language)